Adverum Biotechnologies (NASDAQ:ADVM) Price Target Lowered to $22.00 at Mizuho

Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its target price trimmed by Mizuho from $40.00 to $22.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research analysts also recently issued reports on the company. StockNews.com raised Adverum Biotechnologies […]

Related Keywords

Monaco ,James Paul Scopa ,Nasdaq ,Adverum Biotechnologies Company Profile ,Capital Management ,Adverum Biotechnologies Inc ,Newtyn Management ,Securities Exchange Commission ,Citigroup Inc ,Adverum Biotechnologies ,Free Report ,Moderate Buy ,Get Free Report ,Director James Paul Scopa ,Exchange Commission ,Asset Management ,Apexium Financial ,Adverum Biotechnologies Daily ,Nasdaq Advm ,Advm ,Medical ,Lower Price Target ,Mizuho ,